Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2021 | Story Leonie Bolleurs
Famelab
Abdullahi Jamiu, who is working on his master's degree in Microbiology, was adjudicated as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi Jamiu, who is working on his master's degree in Microbiology in the Department of Microbiology and Biochemistry at the University of the Free State (UFS), was recently announced as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi, who plans on pursuing a doctoral degree after his master’s, says he wants to establish himself as an academic in microbiology.

Making science simple
He says he decided to participate in the FameLab competition because he is very passionate about communicating science. “Science communication affords me the opportunity to not only take my research outside of the lab space, but also to communicate it to the lay audience. Moreover, science is often perceived by the general public as difficult and unfathomable. As such, science communication programmes promote the simplification and better understanding of scientific knowledge in the community,” he says.

FameLab is coordinated by the South African Agency for Science and Technology Advancement, the British Council, and Jive Media Africa.

According to Abdullahi, the experience was mind-blowing. “It gave me the opportunity to compress my 200-page master's thesis into a three-minute talk in a way I had never thought was possible. Having to present virtually and adjust to the ‘new normal’ was quite challenging,” he adds.

“The overall experience was enlightening and engaging, and at the same time entertaining,” says Abdullahi.

Impressing the judges with his charisma, engagement with the audience, and use of props, Abdullahi’s presentation focused on how the exploration and exploitation of a ‘combination therapy’ approach to drug discovery could help to effectively combat fungal infections, which are the common comorbidities in immune-compromised individuals, including those living with HIV, cancer, and COVID-19.

Revealing an enigma
His fascination with microbiology started at a young age. “How very tiny, microscopic creatures, invisible to the unaided eye, are able to infect and sometimes kill both healthy and immune-compromised individuals, was an enigma to me as a little boy. My desire to unravel this mystery triggered my interest in microbiology, and the more I learn, the more enthusiastic I become to broaden my horizon in this challenging yet exciting field of study,” he says.

Abdullahi would like to one day make a difference by conducting relevant research aimed at contributing to finding lasting solutions to the lingering menace posed by pathogenic microbes. “Moreover, I am very passionate about facilitating the transfer of scientific knowledge to the next generation,” Abdullahi concludes.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept